Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

77 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Extensive skin necrosis.
Kurta AO, Piao J, Hurley MY, Abate M. Kurta AO, et al. Among authors: hurley my. JAAD Case Rep. 2018 Dec 6;5(1):66-68. doi: 10.1016/j.jdcr.2018.10.017. eCollection 2019 Jan. JAAD Case Rep. 2018. PMID: 30560189 Free PMC article. No abstract available.
Muir-Torre syndrome appropriate use criteria: Effect of patient age on appropriate use scores.
Task Force/Committee Members; Vidal CI, Sutton A, Armbrect EA, Lee JB, Litzner BR, Hurley MY; Rating Panel; Alam M, Duncan LM, Elston DM, Emanuel PO, Ferringer T, Fung MA, Hosler GA, Lazar AJ, Lowe L, Plaza JA, Robinson JK, Schaffer A. Task Force/Committee Members, et al. Among authors: hurley my. J Cutan Pathol. 2019 Jul;46(7):484-489. doi: 10.1111/cup.13459. Epub 2019 Apr 26. J Cutan Pathol. 2019. PMID: 30895633 Free article.
Plaque-Type Syringoma Masquerading as Microcystic Adnexal Carcinoma: Review of the Literature and Description of a Novel Technique That Emphasizes Lesion Architecture to Help Make the Diagnosis.
Clark M, Duprey C, Sutton A, Pelster MW, Maher IA, Hurley MY, Vidal C. Clark M, et al. Among authors: hurley my. Am J Dermatopathol. 2019 Sep;41(9):e98-e101. doi: 10.1097/DAD.0000000000001415. Am J Dermatopathol. 2019. PMID: 30921007 Review. No abstract available.
Efficacy, rate of tumor response, and safety of a short course (12-24 weeks) of oral vismodegib in various histologic subtypes (infiltrative, nodular, and superficial) of high-risk or locally advanced basal cell carcinoma, in an open-label, prospective case series clinical trial.
Fosko SW, Chu MB, Armbrecht E, Galperin T, Potts GA, Mattox A, Kurta A, Polito K, Slutsky JB, Burkemper NM, Hurley MY. Fosko SW, et al. Among authors: hurley my. J Am Acad Dermatol. 2020 Apr;82(4):946-954. doi: 10.1016/j.jaad.2019.12.002. Epub 2019 Dec 10. J Am Acad Dermatol. 2020. PMID: 31836564 Clinical Trial.
77 results